Displaying drugs 951 - 975 of 1929 in total
Saruparib
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
CRA_9076
Experimental
AZD-9056
AZD9056 has been used in trials studying the basic science and treatment of Rheumatoid Arthritis.
Investigational
CC-90001
Investigational
Ifinatamab deruxtecan
Investigational
PV903
PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.
Investigational
TNG908
TNG908 is a small molecule inhibitor of protein arginine methyl transferase 5 (PRMT5).
Investigational
SNX-2112
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.
Investigational
Matched Description: … SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.[A253137] …
OMS906
OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.
Investigational
Asvasiran
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
BBM-H901
BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.
Investigational
AP-001
Investigational
INS018_055
Investigational
Pemtumomab
Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. It targets the mucin 1 (MUC1) protein.
Investigational
Matched Description: … Pemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. …
RU90395
Experimental
Perospirone
Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors. It also displays affinity towards 5HT1A receptors as a partial agonist. Dainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as...
Experimental
Tenocyclidine
Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Experimental
Illicit
Investigational
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
R906289
R906289 is under investigation in clinical trial NCT05308264 (Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)).
Investigational
IKT-001Pro
Investigational
Tanespimycin
Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
Investigational
Matched Description: … manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 …
Brogidirsen
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
MPT-0L055
Investigational
Displaying drugs 951 - 975 of 1929 in total